FMO6P

Across TCGA pan-cancer cohorts, FMO6P mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FMO6P data layer compared with 21 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher FMO6P mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated FMO6P expression acts as an unfavorable survival marker.

CCRCC, GBM, and HNSC are the cancer types where FMO6P mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.853	1.000	.042	4	view →
GBM	DFS	Tertile	All	0.647	0.798	.035	3	view →
HNSC	OS	Median	II,III,IV	0.946	1.000	.019	3	view →
LUAD	OS	Quartile	All	0.610	1.000	.025	2	view →
LSCC	DFS	Median	II,III,IV	0.355	0.821	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FMO6P–CCRCC (OS)

Open the CCRCC breakdown →